The Food and Drug Administration announced on November 9 that manufacturers of GLP‑1 receptor agonists must add a warning about a rare eye condition called non‑arteritic anterior ischemic optic neuropathy (NAION). The warning applies to popular products such as Ozempic, Wegovy, Zepbound and Mounjaro.
What is NAION?
NAION is a painless, sudden loss of vision that typically affects one eye and can be permanent. It does not usually cause total blindness but can blur or block part of a person’s visual field. About 1 in 200,000 people in the general population develop the condition, with rates rising after age 50.
Why the FDA is acting
Researchers have observed an association between GLP‑1 use and NAION. A 2024 study of 1,700 patients at a Boston neuro‑ophthalmology clinic found that among 169 diabetic patients treated with semaglutide, 17 developed NAION – a rate roughly four times higher than patients not on GLP‑1s. Among 254 patients using semaglutide for obesity, 20 cases were reported, about seven times higher than the non‑GLP‑1 group. Because the clinic’s patients already had risk factors such as diabetes, hypertension, high cholesterol and sleep apnea, the overall incidence was higher than in the broader population.
FDA’s broader review
The agency also performed a meta‑analysis of 126 clinical trials that included 134,253 participants – about 78,200 who received a GLP‑1 drug and 56,000 who received a placebo or another blood‑sugar medication. The analysis identified ten probable NAION cases among GLP‑1 users versus five cases in the control group, indicating a 1.7‑fold increased risk.
What the warning means for patients
Dr. Scott Kahan, a weight‑loss medicine specialist, said the risk is real but still very rare. He emphasized that the warning is an “abundance of caution” and does not change his prescribing practices. Patients taking GLP‑1 medications should discuss any pre‑existing eye conditions with their doctors and be alert for sudden vision changes. They should not stop their medication without medical guidance.
How the warning will appear
Manufacturers will update the safety information sheets that accompany Ozempic, Wegovy, Zepbound, Mounjaro and other GLP‑1 products. The new label will describe NAION, its symptoms, and advise patients to seek immediate ophthalmologic evaluation if they notice sudden visual loss.
Context and next steps
GLP‑1 drugs have become widely prescribed for type 2 diabetes and obesity, with roughly 15 % of Americans having used them at some point. While the FDA’s action highlights a potential rare side effect, the overall benefits of these medications for blood‑sugar control and weight management remain significant. Ongoing research will continue to monitor eye‑health outcomes as more patients receive GLP‑1 therapy.
Original reporting: 40/29 / KHBS (NW Arkansas) — read the source article.
